Sagimet Biosciences Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
SGMT$10.89+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows (unaudited)
CONDENSED STATEMENTS OF CASH FLOWS
(in thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Three Months Ended March 31, | ||||||
| · · 2025 · · 2024 | ||||||
| Cash flows from operating activities · · | ||||||
| Net loss | | $(18,176) | | $(6,629) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | ||||
| Accretion of discount on marketable securities | | (535) | | (193) | ||
| Non-cash operating lease expense | | 39 | | 36 | ||
| Stock-based compensation expense | | 1,472 | | 759 | ||
| Changes in operating assets and liabilities: | | | | | ||
| Prepaid expenses and other current assets | | (687) | | 640 | ||
| Accounts payable, accrued expenses and other current liabilities | | 3,390 | | (782) | ||
| Operating lease liabilities | | (39) | | (39) | ||
| Net cash used in operating activities | | (14,536) | | (6,208) | ||
| Cash flows from investing activities | | | ||||
| Purchases of marketable securities | | | (15,575) | | | — |
| Sales and maturities of marketable securities | | 18,988 | | 3,000 | ||
| Net cash provided by investing activities | | 3,413 | | 3,000 | ||
| Cash flows from financing activities | | | ||||
| Proceeds from sale of Series A common stock, net of issuance costs | | | — | | | 105,750 |
| Payment of financing costs | | — | | (1,018) | ||
| Proceeds from exercise of stock options | | | — | | | 114 |
| Net cash provided by financing activities | | — | | 104,846 | ||
| Net (decrease) increase in cash and cash equivalents | | (11,123) | | 101,638 | ||
| Cash and cash equivalents at beginning of period | | 75,840 | | 75,139 | ||
| Cash and cash equivalents at end of period | | $64,717 | | $176,777 | ||
| | | | | | | |
| Supplemental non-cash investing and financing activities: | | | | | | |
| Deferred financing costs within accounts payable and accrued expenses | | $245 | | $— | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.